Lundbeck acquired Abide Therapeutics and their lead compound ABX-1431

Jun 1, 2019

Updated: Jun 3, 2019

Lundbeck has completed the acquisition of US-based biotech company Abide Therapeutics and the lead compound ABX-1431.

On May 6th, 2019 Lundbeck announced that it was acquiring Abide Therapeutics. Abide Therapeutics is currently working the serine hydrolases; the acquisition helps

Lundbeck to work on new classes of drugs for a range of therapeutic activities.

Also, Lundbeck gets the advanced compound ABX-1431 first-in-class MAG Lipase inhibitor used for the treatment of Tourette Syndrome and neuropathic pain.

Recent Posts

See All

Bristol Myers Squibb Unveils Promising Results from CheckMate -8HW Trial on Combination Opdivo + Yervoy for Metastatic Colorectal Cancer | iPharmaCenter

Bristol Myers Squibb has shared groundbreaking findings from the CheckMate -8HW trial, which examined the combination of nivolumab and...

Sarclisa Receives EU Approval as First Anti-CD38 Therapy for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Sanofi announced that Sarclisa (isatuximab) has been approved by the European Union (EU) for use in combination with the standard-of-care...

Top pharmaceutical companies by revenues in 2024 | Biggest Pharma of 2024 | Top Pharma profits | iPharmaCenter

Lundbeck acquired Abide Therapeutics and their lead compound ABX-1431

Recent Posts

Comments